DRD2 genotypic and haplotype variation is associated with improvements in negative symptoms after 6 weeks' amisulpride treatment

Seung Gul Kang, Kyoung Sae Na, Heon-Jeong Lee, Ik Seung Chee, Kwanghun Lee, Jonghun Lee

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

The aim of this study was to identify the association between the rs1079597 and rs1800497 genetic polymorphisms of the gene encoding the dopamine D 2 receptor (DRD2) protein and the treatment response to the selective dopamine receptor antagonist amisulpride. After 6 weeks of treatment with amisulpride, 125 schizophrenia patients were interviewed based on the Positive and Negative Syndrome Scale and the Clinical Global Impression-Severity Scale. Genotyping for rs1079597 and rs1800497 was performed using the TaqMan single nucleotide polymorphism genotyping assay. There were significant differences in the genotype frequency of the recessive model (χ 2 = 5.73, P = 0.017) and allele frequency (χ 2 = 5.16, P = 0.023) of rs1079597 between the responders and nonresponders based on the Positive and Negative Syndrome Scale negative symptoms scores. There was no significant finding in this regard for the rs1800497 polymorphism. The T-C and C-C haplotype of rs1079597-rs1800497 were associated with the negative symptom treatment response to amisulpride after permutation test. To the best of our knowledge, this is the first report of the positive finding in the association study between rs1079597 polymorphism and the treatment response to amisulpride in schizophrenic patients. A larger scale study involving more single nucleotide polymorphisms of DRD2 will progress the research into the pharmacogenetics of the treatment response to amisulpride.

Original languageEnglish
Pages (from-to)158-162
Number of pages5
JournalJournal of Clinical Psychopharmacology
Volume35
Issue number2
DOIs
Publication statusPublished - 2015 Apr 12

Fingerprint

Haplotypes
Single Nucleotide Polymorphism
Therapeutics
Dopamine Antagonists
Pharmacogenetics
Genetic Polymorphisms
Gene Frequency
Dopamine
Schizophrenia
Genotype
sultopride
Research
Genes
Proteins

Keywords

  • amisulpride
  • DRD2 gene
  • negative symptom treatment response
  • rs1079597
  • rs1800497

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

DRD2 genotypic and haplotype variation is associated with improvements in negative symptoms after 6 weeks' amisulpride treatment. / Kang, Seung Gul; Na, Kyoung Sae; Lee, Heon-Jeong; Chee, Ik Seung; Lee, Kwanghun; Lee, Jonghun.

In: Journal of Clinical Psychopharmacology, Vol. 35, No. 2, 12.04.2015, p. 158-162.

Research output: Contribution to journalArticle

Kang, Seung Gul ; Na, Kyoung Sae ; Lee, Heon-Jeong ; Chee, Ik Seung ; Lee, Kwanghun ; Lee, Jonghun. / DRD2 genotypic and haplotype variation is associated with improvements in negative symptoms after 6 weeks' amisulpride treatment. In: Journal of Clinical Psychopharmacology. 2015 ; Vol. 35, No. 2. pp. 158-162.
@article{904f922d32b7472ca6f5d0a5d495449a,
title = "DRD2 genotypic and haplotype variation is associated with improvements in negative symptoms after 6 weeks' amisulpride treatment",
abstract = "The aim of this study was to identify the association between the rs1079597 and rs1800497 genetic polymorphisms of the gene encoding the dopamine D 2 receptor (DRD2) protein and the treatment response to the selective dopamine receptor antagonist amisulpride. After 6 weeks of treatment with amisulpride, 125 schizophrenia patients were interviewed based on the Positive and Negative Syndrome Scale and the Clinical Global Impression-Severity Scale. Genotyping for rs1079597 and rs1800497 was performed using the TaqMan single nucleotide polymorphism genotyping assay. There were significant differences in the genotype frequency of the recessive model (χ 2 = 5.73, P = 0.017) and allele frequency (χ 2 = 5.16, P = 0.023) of rs1079597 between the responders and nonresponders based on the Positive and Negative Syndrome Scale negative symptoms scores. There was no significant finding in this regard for the rs1800497 polymorphism. The T-C and C-C haplotype of rs1079597-rs1800497 were associated with the negative symptom treatment response to amisulpride after permutation test. To the best of our knowledge, this is the first report of the positive finding in the association study between rs1079597 polymorphism and the treatment response to amisulpride in schizophrenic patients. A larger scale study involving more single nucleotide polymorphisms of DRD2 will progress the research into the pharmacogenetics of the treatment response to amisulpride.",
keywords = "amisulpride, DRD2 gene, negative symptom treatment response, rs1079597, rs1800497",
author = "Kang, {Seung Gul} and Na, {Kyoung Sae} and Heon-Jeong Lee and Chee, {Ik Seung} and Kwanghun Lee and Jonghun Lee",
year = "2015",
month = "4",
day = "12",
doi = "10.1097/JCP.0000000000000294",
language = "English",
volume = "35",
pages = "158--162",
journal = "Journal of Clinical Psychopharmacology",
issn = "0271-0749",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - DRD2 genotypic and haplotype variation is associated with improvements in negative symptoms after 6 weeks' amisulpride treatment

AU - Kang, Seung Gul

AU - Na, Kyoung Sae

AU - Lee, Heon-Jeong

AU - Chee, Ik Seung

AU - Lee, Kwanghun

AU - Lee, Jonghun

PY - 2015/4/12

Y1 - 2015/4/12

N2 - The aim of this study was to identify the association between the rs1079597 and rs1800497 genetic polymorphisms of the gene encoding the dopamine D 2 receptor (DRD2) protein and the treatment response to the selective dopamine receptor antagonist amisulpride. After 6 weeks of treatment with amisulpride, 125 schizophrenia patients were interviewed based on the Positive and Negative Syndrome Scale and the Clinical Global Impression-Severity Scale. Genotyping for rs1079597 and rs1800497 was performed using the TaqMan single nucleotide polymorphism genotyping assay. There were significant differences in the genotype frequency of the recessive model (χ 2 = 5.73, P = 0.017) and allele frequency (χ 2 = 5.16, P = 0.023) of rs1079597 between the responders and nonresponders based on the Positive and Negative Syndrome Scale negative symptoms scores. There was no significant finding in this regard for the rs1800497 polymorphism. The T-C and C-C haplotype of rs1079597-rs1800497 were associated with the negative symptom treatment response to amisulpride after permutation test. To the best of our knowledge, this is the first report of the positive finding in the association study between rs1079597 polymorphism and the treatment response to amisulpride in schizophrenic patients. A larger scale study involving more single nucleotide polymorphisms of DRD2 will progress the research into the pharmacogenetics of the treatment response to amisulpride.

AB - The aim of this study was to identify the association between the rs1079597 and rs1800497 genetic polymorphisms of the gene encoding the dopamine D 2 receptor (DRD2) protein and the treatment response to the selective dopamine receptor antagonist amisulpride. After 6 weeks of treatment with amisulpride, 125 schizophrenia patients were interviewed based on the Positive and Negative Syndrome Scale and the Clinical Global Impression-Severity Scale. Genotyping for rs1079597 and rs1800497 was performed using the TaqMan single nucleotide polymorphism genotyping assay. There were significant differences in the genotype frequency of the recessive model (χ 2 = 5.73, P = 0.017) and allele frequency (χ 2 = 5.16, P = 0.023) of rs1079597 between the responders and nonresponders based on the Positive and Negative Syndrome Scale negative symptoms scores. There was no significant finding in this regard for the rs1800497 polymorphism. The T-C and C-C haplotype of rs1079597-rs1800497 were associated with the negative symptom treatment response to amisulpride after permutation test. To the best of our knowledge, this is the first report of the positive finding in the association study between rs1079597 polymorphism and the treatment response to amisulpride in schizophrenic patients. A larger scale study involving more single nucleotide polymorphisms of DRD2 will progress the research into the pharmacogenetics of the treatment response to amisulpride.

KW - amisulpride

KW - DRD2 gene

KW - negative symptom treatment response

KW - rs1079597

KW - rs1800497

UR - http://www.scopus.com/inward/record.url?scp=84924425521&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924425521&partnerID=8YFLogxK

U2 - 10.1097/JCP.0000000000000294

DO - 10.1097/JCP.0000000000000294

M3 - Article

VL - 35

SP - 158

EP - 162

JO - Journal of Clinical Psychopharmacology

JF - Journal of Clinical Psychopharmacology

SN - 0271-0749

IS - 2

ER -